[Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland]
- PMID: 21861257
[Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland]
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. A cost-of-illness study aims to determine the total economic impact of a disease or health condition on society through the identification, measurement, and valuation of all direct and indirect costs. Exacerbations are believed to be a major cost driver in COPD. The aim of this study was to examine direct, mean costs of COPD in Poland under usual clinical practice form societal perspective.
Material and methods: It was an observational bottom-up-cost-of-illness study, based on a retrospective sample of patients presenting with COPD in pulmonary ambulatory care facilities in Poland. Total medical resources consumption of a sample were collected in 2007/2008 year by physician - lung specialists. Direct costs of COPD were evaluated based on data from different populations of five clinical hospitals and eight out-patient clinics. Resources utilisation and cost data are summarised as mean values per patient per year. 95% confidence intervals were derived using percentile bootstrapping.
Results: Total medicals resources consumption of a COPD patient per year was 1007 EURO (EUR 1 = PLN 4.0; year 2008). Among this cost 606 EURO was directly related to COPD follow up, 105 EURO was related to ambulatory exacerbation, and 296 EURO was related to exacerbation treated in hospital.
Conclusions: The burden of COPD itself appeared to be considerable magnitude for society in Poland.
Similar articles
-
[Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].Pneumonol Alergol Pol. 2008;76(6):426-31. Pneumonol Alergol Pol. 2008. PMID: 19173191 Polish.
-
[Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].Pol Merkur Lekarski. 2009 Mar;26(153):208-14. Pol Merkur Lekarski. 2009. PMID: 19388534 Polish.
-
Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.Respirology. 2008 Sep;13(5):689-94. doi: 10.1111/j.1440-1843.2008.01308.x. Epub 2008 May 29. Respirology. 2008. PMID: 18513247
-
The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.COPD. 2010 Jun;7(3):214-28. doi: 10.3109/15412555.2010.481697. COPD. 2010. PMID: 20486821 Review.
-
[Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics].Pol Merkur Lekarski. 2004 May;16 Suppl 1:5-6, 8. Pol Merkur Lekarski. 2004. PMID: 15524004 Review. Polish.
Cited by
-
Impact of Integrated Care Model (ICM) on Direct Medical Costs in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD).Med Sci Monit. 2017 Jun 12;23:2850-2862. doi: 10.12659/msm.901982. Med Sci Monit. 2017. PMID: 28603270 Free PMC article.
-
Treatment Adherence in Patients with Obstructive Pulmonary Diseases.Int J Environ Res Public Health. 2022 Sep 14;19(18):11573. doi: 10.3390/ijerph191811573. Int J Environ Res Public Health. 2022. PMID: 36141843 Free PMC article.
-
Reducing global inequities in medical oxygen access: the Lancet Global Health Commission on medical oxygen security.Lancet Glob Health. 2025 Mar;13(3):e528-e584. doi: 10.1016/S2214-109X(24)00496-0. Epub 2025 Feb 17. Lancet Glob Health. 2025. PMID: 39978385 Free PMC article. Review. No abstract available.
-
Epidemiological Characteristics of 101,471 Patients Hospitalized with Chronic Obstructive Pulmonary Disease (COPD) in Poland in 2019: Multimorbidity, Duration of Hospitalization, In-Hospital Mortality.Adv Respir Med. 2023 Sep 20;91(5):368-382. doi: 10.3390/arm91050029. Adv Respir Med. 2023. PMID: 37736975 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical